PE
Pharma Equity Group A/S
PEG.CO · CPH
0.08 kr -2.06% (-0.00 kr)
1M -4.75%
Market Cap 93.5M kr
P/E Ratio -
Div. Yield -
ROE 72.77%
Bulios Fair Price
0.04 kr
47.5% downside
Current Price
0.076 kr
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PEG.CO is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
55 /100
Fair P/B 3.67x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 17.91%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
0 /100
Poor ROIC 72.48%
ROE 72.77%
Asset turnover 0.00x
Debt
69 /100
Low Debt/Equity 0.32x
Current ratio 4.33x
Int. coverage -9.52x
Stability
33 /100
Unstable Beta 1.01x
EPS volatility 77.34%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PEG.CO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Christian Henrik Tange
Employees
5
Headquarters
Horsholm